<- Back to digest

European Spine Journal - 2026-10-26 - Journal Article

Age, tumor size, and therapy timing are associated with survival in primary spinal Ewing sarcoma: a nationwide analysis.

ElNemer W, Ghaith AK, Selim O, Yang L, Davidson A, Dardick J, Khalifeh J, Xia Y, Azad T, Theodore N, Lubelski D

database studyLOE IIIn = 413N/A (OS assessed at latest follow-up; specific duration not reported)

Topics

spineoncology
PMID: 42928284DOI: 10.1007/s00586-026-10329-0View on PubMed ->

Key Takeaway

In 413 patients with primary spinal Ewing sarcoma, metastasis conferred a 4.41-fold mortality hazard, adults had nearly double the mortality of pediatric patients (48% vs. 25%), and chemotherapy initiation within 18 days was associated with improved survival in non-metastatic and large-tumor subgroups.

Summary Depth

Choose how much analysis to show on this article page.

Summary

This study queried the National Cancer Database (2004–2017) to identify prognostic factors and optimal treatment timing in primary spinal Ewing sarcoma. SHAP-based feature importance from an Extra Survival Trees model (concordance index 0.80) identified tumor size (HR 1.01/mm), age (HR 1.04/year), and metastasis (HR 4.41) as dominant mortality predictors, with ROC-derived size thresholds of 64 mm in children and 46 mm in adults. In adults, surgery plus radiation favored large tumors (HR 0.77) while surgery plus chemotherapy favored small tumors (HR 0.46), and chemotherapy initiation under 18 days was associated with improved OS in non-metastatic and large-tumor subgroups.

Key Limitation

The cohort predates uniform adoption of interval-compressed chemotherapy and contemporary proton/IMRT radiation practice, limiting applicability to current treatment paradigms.

Original Abstract

BACKGROUND

Primary spinal Ewing sarcoma (EwS) is a rare, aggressive small round cell tumor. While age, tumor size, and metastatic status are established prognostic factors in extremity disease, their impact in spinal primaries remains poorly defined, and the optimal timing of multimodal therapy is uncertain.

OBJECTIVE

To evaluate the prognostic significance of age, tumor size, and treatment timing in primary spinal EwS using a large national database.

METHODS

The National Cancer Database was queried for patients diagnosed with primary spinal EwS between 2004 and 2017. Demographic, clinical, and treatment variables including surgery, chemotherapy, radiation dose/fractionation, and time to local therapy were collected. Overall survival (OS) was assessed by Kaplan-Meier and log-rank testing. Of the five machine-learning survival models that were trained, Extra Survival Trees demonstrated the highest discrimination (concordance index 0.80, integrated Brier score 0.13) and was used for feature importance analysis via SHapley Additive exPlanations (SHAP). Receiver operating characteristic analyses identified prognostic thresholds for age, tumor size, and initiation of chemotherapy.

RESULTS

Among 413 patients (204 pediatric, 219 adult; mean age 24 years), 37% died at latest follow-up. Adults had higher mortality (48% vs. 25%, p < 0.001) and longer delays to chemotherapy initiation (41 vs. 19 days, p < 0.001). SHAP analysis highlighted tumor size (HR 1.01 per mm, p = 0.001), age (HR 1.04 per year, p < 0.001), and metastasis (HR 4.41, p < 0.001) as dominant mortality predictors. Optimal size thresholds were < 64 mm for children and < 46 mm for adults. In adults, surgery with radiation was associated with longer OS in large tumors (HR 0.77, p = 0.044), whereas surgery with chemotherapy was associated with the greatest benefit in small tumors (HR 0.46, p = 0.002). Earlier chemotherapy initiation (< 18 days) was associated with longer survival in non-metastatic and large-tumor subgroups.

CONCLUSIONS

Age, tumor size, and timely initiation of chemotherapy are strongly associated with survival in primary spinal EwS. Local therapy associations varied by tumor size and age, but these non-randomized comparisons are subject to confounding by indication. Because this cohort spans 2004 to 2017 and predates uniform adoption of interval-compressed chemotherapy and contemporary radiation practice, these findings may not fully reflect current outcomes. Early multidisciplinary coordination to expedite chemotherapy remains a reasonable target. Of note, these modality comparisons are non-randomized and are subject to confounding by indication.